(Reuters) -AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal ...
Jacek Olczak, Philip Morris International CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings.
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results